Researchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Bavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
Mithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
A German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
The EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.